sevelamer carbonate (Renvela)

following an abbreviated submission

sevelamer carbonate (Renvela®) is accepted for restricted use within NHS Scotland.

Indication under review: for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.

SMC restriction: the second-line management of hyperphosphataemia in adult patients receiving haemodialysis.

Sevelamer carbonate has been shown to be therapeutically equivalent to sevelamer hydrochloride in reducing serum phosphorus in patients with chronic kidney disease on haemodialysis. For patients in whom sevelamer hydrochloride is an appropriate choice of phosphate binder, the carbonate salt provides an alternative at no additional cost.

Sevelamer carbonate is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/L. As the manufacturer’s submission related only to the control of hyperphosphataemia in adult patients receiving haemodialysis SMC cannot recommend the use of sevelamer carbonate in pre-dialysis patients or in peritoneal dialysis patients.